Skip to main content

Table 5 SBRT of abdominal lymph node oligometastases

From: Stereotactic body radiation therapy for abdominal oligometastases: a biological and clinical review

 

Patients (N)

Primary cancer

Dose (Gy) × fr

Median follow up (mos)

Outcomes

Jereczek-Fossa et al. 2009 [53]

14

Prostate

33 (mean) × 3-5

Mean 18.6

- No in-field clinical progression

     

- Distant or regional LN progression at mean time of 12.7 mo

     

- All patients with relapse had high-risk disease

Bignardi et al. 2011 [54]

19

CRC (5/19)

45 × 6

12

Actuarial rate of freedom from local progression: 77.8 ± 13.9 at both 12 and 24 mos

     

Minimal acute and chronic toxicity

Choi et al. 2010 [55]

30

Uterus and cervix

EBRT: 27–45 (n = 4 pts)

15

4-year LC rate: 67.4%

   

SBRT: 33–45 × 3 (n = 24 pts)

 

4-year OS rate: 50.1%

     

(all 30 pts).

Kim et al. 2009 [56]

7

Gastric (salvage aftersurgery)

48 (median) × 3

26

Complete response: n = 5

     

Partial response: n = 2

Kim et al. 2009 [57]

7

CRC

Escalated dose 36–51 × 3

26

Median survival: 37 mos

     

1-year OS: 100%

     

3-year OS: 71.4%

     

G4: intestinal obstruction in 1/7 patients

Bae et al. 2012 [51]

41

CRC

48(45 – 60) × 3

28

-PFS, LC and OS rates

     

3-year rates : 40%, 64%, 60%

     

5-year rates : 40, 57%, 38%

     

-G3 perforation after pelvic LN SBRT;G4 obstruction of para-aortic LN SBRT

  1. EBRT: electron beam radiotherapy; CRC: colorectal cancer; LN: lymph node; LC: local control, OS: overall survival, G: grade.